An Educational Model Based in Real Drug Candidates

The Discover and Transfer strategic agreement is one of our new incorporation into the educational programs. In fact, it is something never seen before. Throughout these masters the students will be working with current investigations of prestigious research institutes of Barcelona, following up their discoveries and working with their patents by the elaboration of consulting plans in drug discovery. The developments are mentor by our board of professors and they will be working in scientific and regulatory development, preclinical and clinical forecasting, investment and licensing.

It represents a new way of strategic collaboration between a business school and research centers with master and postgraduate students from the science to the technology transfer. At the BBI we want to be at the vanguard of the innovation as much as in business education as in biomedical research. That is why, the Discover and Transfer program promotes scientific and business profiles high qualified and supports technology transfers processes in new drug discoveries.     





“p38mam new combination therapy for breast tumours, with selection marker”

“novel regulation of retinoblastoma (RB) creates a super-repressor for cancer treatment”

“novel set of markers to select active adipose stem cells (asc) for improving efficacy of cell therapy in inflammatory diseases”

“new target-modulating small molecules for the treatment of NAFLD, Non-alcoholic fatty liver disease”

“Portable device for molecular diagnosis (PDMD)”

“βPFO A promising new target against Alzheimer’s disease”

“Oncoselective mechanism for gene or viral therapy”

"Maxphox - Novel cost saving catalyst for aymmetric hyrogenation if enamides"


Discover & Transfer Press Release